BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2025 6:25:19 AM | Browse: 5 | Download: 46
 |
Received |
|
2025-06-05 14:32 |
|
Peer-Review Started |
|
2025-06-05 14:32 |
|
First Decision by Editorial Office Director |
|
2025-06-27 05:23 |
|
Return for Revision |
|
2025-06-27 05:23 |
|
Revised |
|
2025-07-05 10:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-10 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-11 05:45 |
|
Articles in Press |
|
2025-11-11 05:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-10 00:51 |
|
Publish the Manuscript Online |
|
2025-12-23 06:25 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Immune therapy-related hyperprogressive disease: Molecular mechanisms, biomarkers, and clinical strategies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Ming Zhang, Fei-Yu Zhao, Lin-Feng Gao, Tao Xu, Fan Yang and Nian-Song Qian |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nian-Song Qian, Chief Physician, MD, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. A17 Heishanhu Road, Haidian District, Beijing 100091, China. qianniansong1@163.com |
| Key Words |
Hyperprogressive disease; Immune checkpoint inhibitors; Tumor microenvironment; Regulatory T cells; Predictive biomarkers; Combination therapy |
| Core Tip |
Immune checkpoint inhibitor-induced hyperprogressive disease represents a paradoxical clinical phenomenon characterized by accelerated tumor progression mediated through complex immunosuppressive mechanisms involving regulatory T cells expansion, M2-type tumor-associated macrophages polarization, and myeloid-derived suppressor cells accumulation within the tumor microenvironment, coupled with oncogenic alterations such as MDM2 amplification and EGFR activation. Current predictive approaches integrate liquid biopsy profiling (e.g., circulating tumor DNA and blood tumor mutational burden dynamics) with systemic inflammatory markers (e.g., neutrophil-to-lymphocyte ratio and lactate dehydrogenase ratios), while emerging therapeutic strategies focus on combinatorial approaches targeting immunosuppressive networks, metabolic reprogramming, and checkpoint inhibition. This multifaceted pathogenesis underscores the critical need for mechanistic elucidation and translational development of precision management algorithms to mitigate this life-threatening complication of cancer immunotherapy. |
| Publish Date |
2025-12-23 06:25 |
| Citation |
Zhang XM, Zhao FY, Gao LF, Xu T, Yang F, Qian NS. Immune therapy-related hyperprogressive disease: Molecular mechanisms, biomarkers, and clinical strategies. World J Clin Oncol 2025; 16(12): 110351 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i12/110351.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i12.110351 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
